Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

被引:11
作者
Jaradat, Sara K. [1 ]
Ayoub, Nehad M. [1 ]
Al Sharie, Ahmed H. [2 ]
Aldaod, Julia M. [1 ]
机构
[1] Jordan Univ Sci & Technol JUST, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan
[2] Jordan Univ Sci & Technol JUST, Fac Med, Dept Pathol & Microbiol, Irbid, Jordan
关键词
triple-negative breast cancer; receptor tyrosine kinases; small-molecule inhibitors; EGFR; MET; AXL; GROWTH-FACTOR RECEPTOR; POTENTIAL THERAPEUTIC TARGET; FACTOR-I RECEPTOR; GENE COPY NUMBER; CELL LUNG-CANCER; C-KIT; BIOLOGICAL SUBTYPES; CABOZANTINIB XL184; INHIBITS GROWTH; DOWN-REGULATION;
D O I
10.1177/15330338241234780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors. Nevertheless, the success of chemotherapeutic treatments is limited by their toxicity and development of acquired resistance leading to therapeutic failure and tumor relapse. Hence, there is an urgent need to explore novel targeted therapies for TNBC. Receptor tyrosine kinases (RTKs) are a family of transmembrane receptors that are key regulators of intracellular signaling pathways controlling cell proliferation, differentiation, survival, and motility. Aberrant activity and/or expression of several types of RTKs have been strongly connected to tumorigenesis. RTKs are frequently overexpressed and/or deregulated in triple-negative breast tumors and are further associated with tumor progression and reduced survival in patients. Therefore, targeting RTKs could be an appealing therapeutic strategy for the treatment of TNBC. This review summarizes the current evidence regarding the antitumor activity of RTK inhibitors in preclinical models of TNBC. The review also provides insights into the clinical trials evaluating the use of RTK inhibitors for the treatment of patients with TNBC.
引用
收藏
页数:20
相关论文
共 183 条
[61]   Inhibition of c-Kit by tyrosine kinase inhibitors [J].
Galanis, Allison ;
Levis, Mark .
HAEMATOLOGICA, 2015, 100 (03) :E77-E79
[62]   Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target [J].
Gandhi, Leena ;
Jaenne, Pasi A. .
CLINICAL CANCER RESEARCH, 2012, 18 (14) :3737-3742
[63]   Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers [J].
Gao, Hong-Fei ;
Yang, Ci-Qiu ;
Cheng, Min-Yi ;
Zhu, Teng ;
Yang, Mei ;
Zhang, Liu-Lu ;
Wang, Kun .
CLINICAL BREAST CANCER, 2018, 18 (05) :E961-E966
[64]   Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors [J].
Garcia-Foncillas, Jesus ;
Sunakawa, Yu ;
Aderka, Dan ;
Wainberg, Zev ;
Ronga, Philippe ;
Witzler, Pauline ;
Stintzing, Sebastian .
FRONTIERS IN ONCOLOGY, 2019, 9
[65]   HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials [J].
Gennari, Alessandra ;
Sormani, Maria Pia ;
Pronzato, Paolo ;
Puntoni, Matteo ;
Colozza, Mariantonietta ;
Pfeffer, Ulrich ;
Bruzzi, Paolo .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) :14-20
[66]   Triple-negative breast cancer-current status and future directions [J].
Gluz, O. ;
Liedtke, C. ;
Gottschalk, N. ;
Pusztai, L. ;
Nitz, U. ;
Harbeck, N. .
ANNALS OF ONCOLOGY, 2009, 20 (12) :1913-1927
[67]   Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer [J].
Hamilton, Nalo ;
Austin, David ;
Marquez-Garban, Diana ;
Sanchez, Rudy ;
Chau, Brittney ;
Foos, Kay ;
Wu, Yanyuan ;
Vadgama, Jaydutt ;
Pietras, Richard .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11)
[68]   Epidemiology of Triple-Negative Breast Cancer A Review [J].
Howard, Frederick M. ;
Olopade, Olufunmilayo, I .
CANCER JOURNAL, 2021, 27 (01) :8-16
[69]   Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer [J].
Hsu, Yi-Hsin ;
Yao, Jun ;
Chan, Li-Chuan ;
Wu, Ting-Jung ;
Hsu, Jennifer L. ;
Fang, Yueh-Fu ;
Wei, Yongkun ;
Wu, Yun ;
Huang, Wen-Chien ;
Liu, Chien-Liang ;
Chang, Yuan-Ching ;
Wang, Ming-Yang ;
Li, Chia-Wei ;
Shen, Jia ;
Chen, Mei-Kuang ;
Sahin, Aysegul A. ;
Sood, Anil ;
Mills, Gordon B. ;
Yu, Dihua ;
Hortobagyi, Gabriel N. ;
Hung, Mien-Chie .
CANCER RESEARCH, 2014, 74 (17) :4822-4835
[70]   Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy [J].
Hua, Hui ;
Kong, Qingbin ;
Yin, Jie ;
Zhang, Jin ;
Jiang, Yangfu .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)